CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round ...
THE WOODLANDS, Texas and HUMMELSTOWN, Pa., March 17, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a ...
State-of-the-art AI model accurately predicting unseen biological experiments X-Cell is trained on X-Atlas/Pisces, the largest and most context-diverse genome-wide perturbation dataset ever reported ...
Entering a cell and watching its entire inner machinery at work, how DNA is copied, how proteins are assembled, or how it splits in two, has been, for decades, an impossible dream. Now, scientists at ...
Sana Biotechnology’s investigational allogeneic islet cell therapy has survived and secreted insulin for more than one year after transplantation in a patient. Sana closed Friday’s trading session at ...
ImmunityBio (IBRX) shares gained on Friday after the cancer drug developer announced the successful conclusion of two manufacturing engineering programs designed to validate its Cytokine-Enriched NK ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results